Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12

Molecular Oncology

Volumn 5, Issue 3, 2011, Pages 242-255

  Malvicini, Mariana ^a   Ingolotti, Mariana ^a   Piccioni, Flavia ^a   Garcia, Mariana ^a,b   Bayo, Juan ^a   Atorrasagasti, Catalina ^a   Alaniz, Laura ^a,b   Aquino, Jorge B ^a,b   Espinoza, Jaime A ^d,e   Gidekel, Manuel ^d   Scharovsky, O Graciela ^c   Matar, Pablo ^b,c   Mazzolini, Guillermo ^a,b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^d UNIVERSIDAD ADOLFO IBÁÑEZ   (Chile)

^e UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Cyclophosphamide; Gastrointestinal carcinoma; IL 12; Immunosuppression; Tregs

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; INTERLEUKIN 10; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GASTROINTESTINAL CARCINOMA; GENE TRANSFER; IMMUNOSUPPRESSIVE TREATMENT; LIVER METASTASIS; LOW DRUG DOSE; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALIA; MUS;

EID: 79957513833     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.03.007     Document Type: Article

References (57)

1. Alaniz L., Rizzo M., Malvicini M., Jaunarena J., Avella D., Atorrasagasti C., Aquino J.B., Garcia M., Matar P., Silva M., Mazzolini G. Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Lett. 2009, 278:9-16.
2. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
3. Appay V., Zaunders J.J., Papagno L., Sutton J., Jaramillo A., Waters A., Easterbrook P., Grey P., Smith D., McMichael A.J., Cooper D.A., Rowland-Jones S.L., Kelleher A.D. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 2002, 168:5954-5958.
4. Barajas M., Mazzolini G., Genove G., Bilbao R., Narvaiza I., Schmitz V., Sangro B., Melero I., Qian C., Prieto J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001, 33:52-61.
5. Bell D., Chomarat P., Broyles D., Netto G., Harb G.M., Lebecque S., Valladeau J., Davoust J., Palucka K.A., Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 1999, 190:1417-1426.
6. Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood 2006, 108:804-811.
7. Bluestone J.A., Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity?. Curr. Opin. Immunol. 2005, 17:638-642.
8. Brodsky R.A., Petri M., Smith B.D., Seifter E.J., Spivak J.L., Styler M., Dang C.V., Brodsky I., Jones R.J. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann. Intern. Med. 1998, 129:1031-1035.
9. Bronte V., Wang M., Overwijk W.W., Surman D.R., Pericle F., Rosenberg S.A., Restifo N.P. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 1998, 161:5313-5320.
10. Caruso M., Pham-Nguyen K., Kwong Y.L., Xu B., Kosai K.I., Finegold M., Woo S.L., Chen S.H. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. U S A 1996, 93:11302-11306.
11. Clark C.E., Beatty G.L., Vonderheide R.H. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 2009, 279:1-7.
12. Colombo M.P., Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?. Immunol. Today 1994, 15:48-51.
13. Colvin O.M. An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des 1999, 5:555-560.
14. Croci D.O., Zacarias Fluck M.F., Rico M.J., Matar P., Rabinovich G.A., Scharovsky O.G. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol. Immunother 2007, 56:1687-1700.
15. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
16. Dieckmann D., Plottner H., Berchtold S., Berger T., Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 2001, 193:1303-1310.
17. Elkord E., Hawkins R.E., Stern P.L. Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin. Biol. Ther. 2008, 8:385-395.
18. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010.
19. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
20. Gabrilovich D.I., Velders M.P., Sotomayor E.M., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 2001, 166:5398-5406.
21. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
22. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., Kroemer G., Martin F., Chauffert B., Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 2005, 202:919-929.
23. Gomez G.G., Hutchison R.B., Kruse C.A. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat. Rev. 2001, 27:375-402.
24. Haigh T.A., Lin X., Jia H., Hui E.P., Chan A.T., Rickinson A.B., Taylor G.S. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J. Immunol. 2008, 180:1643-1654.
25. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
26. Kerkar S.P., Muranski P., Kaiser A., Boni A., Sanchez-Perez L., Yu Z., Palmer D.C., Reger R.N., Borman Z.A., Zhang L., Morgan R.A., Gattinoni L., Rosenberg S.A., Trinchieri G., Restifo N.P. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010, 70:6725-6734.
27. Ko J.S., Rayman P., Ireland J., Swaidani S., Li G., Bunting K.D., Rini B., Finke J.H., Cohen P.A. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010, 70:3526-3536.
28. Larmonier N., Marron M., Zeng Y., Cantrell J., Romanoski A., Sepassi M., Thompson S., Chen X., Andreansky S., Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol. Immunother. 2007, 56:48-59.
29. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., Sosman J.A., Dutcher J.P., Vogelzang N.J., Ryan J.L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90:2541-2548.
30. Lorenz M., Staib-Sebler E., Hochmuth K., Heinrich S., Gog C., Vetter G., Encke A., Muller H.H. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin. Oncol. 2000, 27:112-119.
31. Malvicini M., Rizzo M., Alaniz L., Pinero F., Garcia M., Atorrasagasti C., Aquino J.B., Rozados V., Scharovsky O.G., Matar P., Mazzolini G. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin. Cancer Res. 2009, 15:7256-7265.
32. Matar P., Rozados V.R., Gervasoni S.I., Scharovsky G.O. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol. Immunother. 2002, 50:588-596.
33. Mazzolini G., Murillo O., Atorrasagasti C., Dubrot J., Tirapu I., Rizzo M., Arina A., Alfaro C., Azpilicueta A., Berasain C., Perez-Gracia J.L., Gonzalez A., Melero I. Immunotherapy and immunoescape in colorectal cancer. World J. Gastroenterol. 2007, 13:5822-5831.
34. Mazzolini G., Prieto J., Melero I. Gene therapy of cancer with interleukin-12. Curr. Pharm. Des. 2003, 9:1981-1991.
35. Mazzolini G., Qian C., Xie X., Sun Y., Lasarte J.J., Drozdzik M., Prieto J. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther. 1999, 6:514-522.
36. Medina-Echeverz J., Fioravanti J., Zabala M., Ardaiz N., Prieto J., Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 2010, 186:807-815.
37. Melero I., Mazzolini G., Narvaiza I., Qian C., Chen L., Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol. 2001, 22:113-115.
38. Nestle F.O., Burg G., Fah J., Wrone-Smith T., Nickoloff B.J. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol. 1997, 150:641-651.
39. Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. U S A 2008, 105:10113-10118.
40. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65:2457-2464.
41. Proietti E., Greco G., Garrone B., Baccarini S., Mauri C., Venditti M., Carlei D., Belardelli F. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 1998, 101:429-441.
42. Putzer B.M., Stiewe T., Rodicker F., Schildgen O., Ruhm S., Dirsch O., Fiedler M., Damen U., Tennant B., Scherer C., Graham F.L., Roggendorf M. Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J. Natl. Cancer Inst. 2001, 93:472-479.
43. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
44. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., Kuniyasu Y., Nomura T., Toda M., Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001, 182:18-32.
45. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I., Benito A., Larrache J., Pueyo J., Subtil J.C., Olague C., Sola J., Sadaba B., Lacasa C., Melero I., Qian C., Prieto J. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 2004, 22:1389-1397.
46. Shapira S., Lisiansky V., Arber N., Kraus S. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opin. Investig. Drugs 2010, 19(Suppl 1):S67-S77.
47. Spaapen R.M., Groen R.W., van den Oudenalder K., Guichelaar T., van Elk M., Aarts-Riemens T., Bloem A.C., Storm G., Martens A.C., Lokhorst H.M., Mutis T. Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen. Clin. Cancer Res. 2010, 16:5481-5488.
48. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
49. Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., Shimizu J., Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998, 10:1969-1980.
50. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 2008, 9:239-244.
51. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188:287-296.
52. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
53. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
54. Yokoyama Y., Dhanabal M., Griffioen A.W., Sukhatme V.P., Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 2000, 60:2190-2196.
55. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
56. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.
57. Zwirner N.W., Croci D.O., Domaica C.I., Rabinovich G.A. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr. Pharm. Des 2010, 16:255-267.